Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02XKD
|
|||
| Former ID |
DNC006903
|
|||
| Drug Name |
3-bromo-4,4',5-trimethoxy-(Z)-stilbene
|
|||
| Synonyms |
SCHEMBL4219422; CHEMBL424885
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H17BrO3
|
|||
| Canonical SMILES |
COC1=CC=C(C=C1)C=CC2=CC(=C(C(=C2)Br)OC)OC
|
|||
| InChI |
1S/C17H17BrO3/c1-19-14-8-6-12(7-9-14)4-5-13-10-15(18)17(21-3)16(11-13)20-2/h4-11H,1-3H3/b5-4-
|
|||
| InChIKey |
HORVHXITWDPZBG-PLNGDYQASA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin beta (TUBB) | Target Info | Inhibitor | [1] |
| Tubulin beta-2 chain (TUBB2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.